Performance Issues Triggering The Recall
On November 11, 2026, Cardinal Health 200, LLC initiated a Class I recall for its Presource PBDS kits, which contain BD Alaris Pump Infusion Sets. The recall specifically targets kits labeled as KIT,C SECTION ADMIT, C, designed for use with the BD Alaris Pump Module Model 8100. The primary driver for this action was the identification of performance issues within the infusion sets themselves. These defects posed a significant risk to patient safety, necessitating immediate removal from the market to prevent potential harm during clinical administration. The urgency of this recall underscores the critical nature of reliable infusion technology in modern healthcare settings, where even minor malfunctions can lead to severe adverse events.
Also worth reading: Are home body composition scales worth purchasing for health tracking? · How reliable is the data provided by wearable health devices? · What is the best Medi-Cal health insurance plan to choose?
The unresolved aspect of this recall centers on the specific nature of the performance failures that rendered the devices unsafe. While the FDA classified this as a Class I recall, indicating the highest level of danger, the precise mechanical or chemical defects causing the malfunction remain detailed in official documentation. Clinicians relying on these systems for critical therapies must verify their inventory against the recalled lot numbers immediately. This situation highlights the broader challenge of maintaining rigorous quality control across complex medical device supply chains, ensuring that every component functions as intended before reaching the patient.
Affected BD Alaris Pump Models
The recall initiated by Cardinal Health 200 LLC on November 11, 2026, specifically targets kits containing BD Alaris Pump Infusion Sets designed for use with the BD Alaris Pump Module Model 8100. These kits, labeled under identifiers such as KIT,C SECTION ADMIT,, C…, were withdrawn due to significant performance issues associated with the infusion sets themselves. This Class I recall highlights a critical failure in device functionality that necessitates immediate attention from healthcare providers and facilities utilizing these specific infusion systems. The performance defect raises serious concerns regarding the accurate delivery of medications, potentially compromising patient safety during critical care procedures.
This incident underscores the broader challenges facing medical device reliability and regulatory oversight within the healthcare sector. As millions of Americans rely on implanted and external medical devices, any malfunction or recall event triggers rigorous protocols to ensure patient safety and mitigate clinician liability. The FDA’s classification of this recall as Class I indicates a situation where use of the product could cause serious adverse health consequences or death. Healthcare networks must urgently verify their inventory against the affected models to prevent further complications and ensure continuous, safe patient care delivery without interruption.
Cardinal Health Presource Kit Details
The FDA initiated a Class I recall on November 11, 2026, targeting Cardinal Health Presource PBDS kits distributed by Cardinal Health 200, LLC. These kits contain BD Alaris Pump Infusion Sets designed for use with the BD Alaris Pump Module Model 8100. The recall specifically addresses kits labeled as KIT,C SECTION ADMIT,, C…. The primary reason for this action is that the included infusion sets were previously recalled due to significant performance issues. This defect poses a direct risk to patient safety, as malfunctioning infusion sets can lead to inaccurate medication delivery or pump failure during critical care procedures.
Cardinal Health 200, LLC issued this recall to mitigate potential harm in clinical settings where these devices are routinely used. The performance issues necessitate immediate removal from the market to prevent adverse events. Clinics and care networks utilizing these kits must verify their inventory against the specific lot numbers and model identifiers mentioned in the official FDA documentation. Failure to comply with this recall could result in serious patient injury and significant liability for healthcare providers. It is essential for medical facilities to act swiftly to replace or return these defective components, ensuring uninterrupted and safe patient care operations without further risk of equipment failure.
Class I Risk Classification Explained
The FDA initiated a Class I recall on November 11, 2026, targeting Cardinal Health 200, LLC for its Presource PBDS kits. These kits contained BD Alaris Pump Infusion Sets designed for use with the BD Alaris Pump Module Model 8100. The agency classified this action as the lowest risk level, indicating that exposure to the recalled product is unlikely to cause adverse health consequences. The recall stemmed from specific performance issues identified within the infusion sets themselves. While the summary notes mention unauthorized marketing as a frequent cause for aesthetic device recalls, this particular action focused strictly on the mechanical or functional reliability of the infusion components rather than marketing violations or drug potency issues.
Understanding these classifications helps care networks mitigate liability and ensure patient safety. Clinics using these specific pumps must immediately verify their inventory against the recall notice. The FDA emphasizes that even Class I recalls require prompt action to prevent potential, albeit minor, complications. By integrating this data into your care-coordination workflows, you can track affected units and notify relevant stakeholders efficiently. This proactive approach aligns with broader industry concerns raised in October 2026 regarding device safety and clinician responsibility. Staying informed about such recalls is essential for maintaining trust and operational integrity within your patient-pulse SaaS ecosystem, ensuring that all medical devices in use meet current safety standards without delay.
Clinician Action Steps Required Now
Cardinal Health 200 LLC initiated a Class I recall on November 11, 2026, for Presource PBDS kits containing BD Alaris Pump Infusion Sets. These kits, specifically labeled as KIT, C SECTION ADMIT, C, were withdrawn due to significant performance issues associated with the infusion sets used alongside the BD Alaris Pump Module Model 8100. This recall highlights critical vulnerabilities in the supply chain for essential infusion components, raising immediate concerns about patient safety and clinical liability. Healthcare providers must urgently verify their inventory to ensure no affected kits remain in use. The FDA’s classification underscores the severity of these performance defects, demanding swift action to prevent potential adverse events. Clinicians should review recent patient treatments involving these specific pumps and sets to identify any individuals who may have been exposed to compromised equipment.
Immediate protocol updates are necessary to mitigate risks associated with this recall. Care coordination teams must communicate directly with affected patients, explaining the situation and scheduling follow-up assessments. It is crucial to document all steps taken in the patient records to maintain transparency and protect against potential liability issues. Additionally, staff should be trained to recognize signs of malfunction in the BD Alaris Pump Module Model 8100. By proactively addressing these concerns, healthcare facilities can uphold their duty of care and ensure patient safety remains the top priority. This recall serves as a stark reminder of the importance of rigorous quality control measures in medical device distribution and usage.
Recalled Infusion Set Specifications
| Manufacturer | Product | Recall Date | Reason |
|---|---|---|---|
| Cardinal Health 200, LLC | Presource PBDS kits | 2026-11-11 | Performance issues |